These forwardlooking statements include without limitation statements relating to our future operations business plans priorities research and development programs SRP9001s potential for accelerated approval the Companys plans to continue working with the FDA as they complete their review of the SRP9001 BLA the potentially transformative benefits of SRP9001 and that the FDA is not bound by the advisory committee recommendation but takes its advice in consideration when reviewing applicationsActual results could materially differ from those stated or implied by these forwardlooking statements as a result of such risks and uncertainties